ALZAMEND NEURO, INC. Costs and Expenses
ALZAMEND NEURO, INC. (ALZN) reported Costs and Expenses of $14.87 million for the 12-month period ending 2023-04-30, per its 10-K filed 2023-07-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2023-07-27
- ALZAMEND NEURO, INC. costs and expenses for the quarter ending 2023-04-30 was $3.31M, a 14.66% decline year-over-year.
- ALZAMEND NEURO, INC. costs and expenses for the quarter ending 2023-01-31 was $5.42M, a 112.14% increase year-over-year.
- ALZAMEND NEURO, INC. costs and expenses for the quarter ending 2022-10-31 was $3.11M, a 13.32% decline year-over-year.
- ALZAMEND NEURO, INC. costs and expenses for the quarter ending 2022-07-31 was $3.04M, a 31.62% increase year-over-year.
- ALZAMEND NEURO, INC. costs and expenses for fiscal 2023 was $14.87M, a 20.71% increase from fiscal 2022.
- ALZAMEND NEURO, INC. costs and expenses for fiscal 2022 was $12.32M, a 148.78% increase from fiscal 2021.
- ALZAMEND NEURO, INC. costs and expenses for fiscal 2021 was $4.95M, a 11.93% increase from fiscal 2020.
- ALZAMEND NEURO, INC. costs and expenses for fiscal 2020 was $4.42M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2023-04-30 | $3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | $8.73M derived: sum of 2 quarters · filed 2023-07-27 | $11.83M derived: sum of 3 quarters · filed 2023-07-27 | $14.87M 10-K · filed 2023-07-27 |
| 2023-01-31 | $5.42M 10-Q · filed 2023-03-15 | $8.53M derived: sum of 2 quarters · filed 2023-03-15 | $11.57M 10-Q · filed 2023-03-15 | $15.44M derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-10-31 | $3.11M 10-Q · filed 2022-12-12 | $6.14M 10-Q · filed 2022-12-12 | $10.01M derived: sum of 3 quarters · filed 2023-07-27 | $12.57M derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-07-31 | $3.04M 10-Q · filed 2022-09-13 | $6.91M derived: sum of 2 quarters · filed 2023-07-27 | $9.46M derived: sum of 3 quarters · filed 2023-07-27 | $13.05M derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-04-30 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | $6.43M derived: sum of 2 quarters · filed 2023-07-27 | $10.01M derived: sum of 3 quarters · filed 2023-07-27 | $12.32M 10-K · filed 2023-07-27 |
| 2022-01-31 | $2.56M 10-Q · filed 2023-03-15 | $6.14M derived: sum of 2 quarters · filed 2023-03-15 | $8.45M 10-Q · filed 2023-03-15 | $9.67M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-10-31 | $3.58M 10-Q · filed 2022-12-12 | $5.89M 10-Q · filed 2022-12-12 | $7.11M derived: sum of 3 quarters · filed 2022-12-12 | $8.23M derived: sum of 4 quarters · filed 2022-12-12 |
| 2021-07-31 | $2.31M 10-Q · filed 2022-09-13 | $3.53M derived: sum of 2 quarters · filed 2022-09-13 | $4.64M derived: sum of 3 quarters · filed 2022-09-13 | $5.94M derived: sum of 4 quarters · filed 2022-09-13 |
| 2021-04-30 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | $2.34M derived: sum of 2 quarters · filed 2022-07-19 | $3.63M derived: sum of 3 quarters · filed 2022-07-19 | $4.95M 10-K · filed 2022-07-19 |
| 2021-01-31 | $1.12M 10-Q · filed 2022-03-15 | $2.41M derived: sum of 2 quarters · filed 2022-03-15 | $3.73M 10-Q · filed 2022-03-15 | |
| 2020-10-31 | $1.30M 10-Q · filed 2021-12-13 | $2.62M 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | $1.32M 10-Q · filed 2021-09-13 | |||
| 2020-04-30 | $4.42M 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |